Hormone replacement therapy prevents bone loss in patients with inflammatory bowel disease.
article
OA: bronze
CC0
⤵ 1 in-corpus citation
Abstract
Patients with inflammatory bowel disease have an increased prevalence of osteoporosis, and suffer high rates of spinal bone loss. Hormone replacement therapy (HRT) is effective in the treatment and prevention of osteoporosis but has not been studied in patients with inflammatory bowel disease. A two year prospective study of HRT in inflammatory bowel disease was performed in 47 postmenopausal women aged 44 to 67 years with ulcerative colitis (25) or Crohn's disease (22). Patients had radial and spinal bone density measured annually by single photon absorptiometry and quantitative computed tomography respectively. The mean (95% confidence intervals) annual change in radial bone density was +1.42%/yr (+0.58 to +2.26; P < 0.005) and for spinal bone +2.60%/yr (+1.06 to +4.15; p < 0.005). There was no significant correlation between rates of change of bone density at the two sites, or between the rates of change and the initial bone density either in the radius or spine. Twelve patients were given prednisolone during the study, and their rates of change for spinal bone density were lower, but values were not statistically significantly different from those who did not receive corticosteroids. Changes in bone density for patients with ulcerative colitis and Crohn's disease were not significantly different. The change in bone density did not correlate with the patients' age or number of years after the menopause. It is concluded that HRT is effective in prevention of bone loss in postmenopausal women with inflammatory bowel disease.
My notes (saved in your browser only)
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (1)
Cited by (1)
References (48)
- Two new combinations of estrogen and progestogen for prevention of postmenopausal bone loss: Long‐term effects on bone, calcium and lipid metabolism, climacteric symptoms and bleeding via openalex
- W115779710 via openalex
- W1486747188 via openalex
- W1546808755 via openalex
- W1561293749 via openalex
- W1643798622 via openalex
- W1964321896 via openalex
- W1966869369 via openalex
- W1970182232 via openalex
- W1972488771 via openalex
- W1975184549 via openalex
- W1978309257 via openalex
- W2002924549 via openalex
- W2004236425 via openalex
- W2004383762 via openalex
- W2006517493 via openalex
- W2006649680 via openalex
- W2013517867 via openalex
- W2018376606 via openalex
- W2020987523 via openalex
- W2022226480 via openalex
- W2027109535 via openalex
- W2046983302 via openalex
- W2052858021 via openalex
- W2053593143 via openalex
- W2059534616 via openalex
- W2067522759 via openalex
- W2077310525 via openalex
- W2078406992 via openalex
- W2078629144 via openalex
- W2083354727 via openalex
- W2088859172 via openalex
- W2092791248 via openalex
- W2093106920 via openalex
- W2099491597 via openalex
- W2102355595 via openalex
- W2109199270 via openalex
- W2154542408 via openalex
- W2162945129 via openalex
- W2304520185 via openalex
- W2315746182 via openalex
- W2341127235 via openalex
- W2426090998 via openalex
- W2461955340 via openalex
- W2742718982 via openalex
- W3012695018 via openalex
- W44375275 via openalex
- W4301019714 via openalex
Cited by (1)
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0
· commercial use OK